While ovarian cancer has lagged behind other solid tumors in the availability of targeted therapies, there are now multiple treatment options including PARP inhibitors, immunotherapy, and NTRK inhibitors in our therapeutic arsenal. The gene discussed is PARP1; the disease is ovarian cancer.